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The novel coronavirus disease of 2019 (COVID-19) pandemic, as declared by the World

Health Organization, is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV2)
[1,2]. Cardiovascular disease and, in particular, venous thromboembolism (VTE) has emerged as an
important consideration in the management of hospitalized patients with COVID-19. The diagnosis of
VTE using standardized objective testing is problematic in these patients, given the risk of infecting
non-COVID-19 hospitalized patients and hospital personnel, coupled with the usual challenges of
performing diagnostic testing in critically-ill patients. Early reports suggest a high incidence of VTE
in hospitalized COVID-19 patients, particularly those with severe illness, that is similar to the high
VTE rates observed in patients with other viral pneumonias, including severe acute respiratory
syndrome (SARS) and Middle East respiratory syndrome (MERS-CoV) [3–6] . COVID-19 is
associated with marked abnormalities in markers of hypercoagulability, including elevated levels of
D-dimer, fibrinogen, and factor VIII, a shortened activated partial thromboplastin time (aPTT) and an
elevated sepsis induced coagulopathy (SIC) score [7] . Investigational therapies for the management
of severely ill COVID-19 patients may carry an increased risk for VTE or have implications for drugdrug interactions with established agents used for the acute and chronic management of VTE, such as
the direct oral anticoagulants (DOACs) and Vitamin K antagonists such as warfarin.
Hospitalized COVID-19 patients share similar strong clinical intrinsic and extrinsic risk

factors for VTE, which include advanced age, obesity, immobility/stroke with paralysis, a history of
cancer/active cancer, management in an intensive care unit (ICU)/coronary care unit (CCU) setting, a
prior history of VTE or known thrombophilia, that are present in hospitalized medically ill patients
[7,8] . However, risk stratification for VTE and the optimal intensity and duration of anticoagulant
thromboprophylaxis, including post-hospital discharge prophylaxis, remains uncertain in hospitalized
COVID-19 patients.
The overall objective of this guidance from the Scientific and Standardization Committee

(SSC) of the ISTH, developed by a multidisciplinary panel of experts in thrombosis and haemostasis,
is to provide practical guidance for the management of VTE in hospitalized patients with suspected or
confirmed COVID-19 infection. Specific objectives are: 1) to provide an approach to the diagnosis of
VTE; 2) to provide guidance on thromboprophylaxis strategies in ICU and non-ICU settings,
including the duration of prophylaxis; and 3) to provide guidance on the treatment of VTE.
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Methods
This guidance statement is a collaborative effort of the Perioperative and Critical Care

Thrombosis and Haemostasis, along with members of the Control of Anticoagulation and
Disseminated Intravascular Coagulation Subcommittees of the SCC. The guidance provided is
anchored on a narrative review of pertinent literature, with a search occurring until April 18, 2020,
coupled with responses to a standardized and independently administered survey of preferred
practices related to the diagnosis, prevention, and treatment of VTE in COVID-19 patients
(Appendix) and conducted by the McMaster Centre for Transfusion Medicine using an independent,
multi-institutional, and multidisciplinary panel of experts in the field of thrombosis and haemostasis.
The survey of experts was done using a single cross-sectional assessment approach with an

expectation that all (100%) panelists would select a pre-specified management option or to indicate,
through the “other option” category that alternative management was preferred. This one-time
approach, rather than a multi-step, iterative approach (e.g., Delphi method), was deemed appropriate
in the context of the topic (COVID-19 and thrombosis) where requisite evidence, typically used in an
iterative approach, is not available. Our aim was to identify where consensus existed and, of equal
importance, to identify where there was a lack of consensus on clinical management.
The Diagnosis of VTE in Hospitalized COVID-19 Patients
The diagnostic assessment of suspected VTE in hospitalized COVID-19 patients is

challenging, especially for critically ill patients in whom, typically, it is important to reliably confirm
or exclude VTE. Imaging studies for deep vein thrombosis (DVT) or pulmonary embolism (PE) may
be avoided due to concerns of transmitting infection in non-COVID-19 hospital wards or to healthcare
workers. The frequent finding of an elevated D-dimer in very ill hospitalized COVID-19 patients may
prompt an aggressive diagnostic approach for VTE, despite the controversy that a very elevated Ddimer (>4.0 mg/L) may not be a reliable predictor of VTE in this population but rather a marker of
poor overall outcome [4,9] . One recent study found a sensitivity of 85.0% and specificity of 88.5%
for diagnosing VTE in patients with D-dimer levels >1.5 mg/L, but the study was based on a small
sample size [4] . Bedside imaging studies such as point-of-care compression ultrasonography to assess
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for lower and upper extremity DVT or bedside echocardiography to assess for right ventricular strain
associated with PE may be difficult to obtain due to patient instability or the requirement of prone
positioning in patients with acute respiratory distress syndrome (ARDS), and may lack sufficient
specificity and sensitivity to diagnose VTE as patients with pneumonia may have right ventricular
strain without PE [10] . However, in the clinical context of unexplained sudden deterioration of
pulmonary status or acute lower extremity erythema or swelling, these tests may be useful in aiding
the clinical suspicion for VTE.
These concerns should be balanced by emerging data that the incidence of VTE in hospitalized

COVID-19 patients with severe pneumonia or in ICU settings is higher than that reported by
historical data in similar patients, with an incidence of VTE of 27% (95% confidence interval [CI]:
17-37) in one study using standard thromboprophylaxis and an incidence of 25% in another study
without prophylaxis [3,4]. These findings are consistent with high rates of VTE in patients with other
severe viral pneumonias, such as influenza H1N1, in whom there was an 18- to 23-fold higher risk for
VTE compared with control patients [5] .
Some clinicians advocate in favor of routine DVT screening in hospitalized COVID-19

patients using bedside venous ultrasound based on the premise that undiagnosed DVT and resultant
PE (including microthrombi-related mechanisms) may be an important contributor to hypoxic
pulmonary vasoconstriction that would lead to pulmonary hypertension and right ventricular failure,
in addition to worsening of ARDS. Whether routine screening with bedside venous ultrasonography
or echocardiography to diagnose DVT and PE is useful in managing thromboprophylaxis strategies in
sick hospitalized COVID-19 patients remains uncertain.
Guidance Statement 1: Diagnosis of VTE in hospitalized COVID-19 patients:
a. Practitioners should use standard-of-care objective testing (i.e., CTPA, V/Q scan, MRI
venography, Doppler ultrasonography) to diagnose VTE based on clinical index of suspicion.
A pragmatic approach (i.e., point-of-care bedside ultrasonography or echocardiography) can
also be combined with standard-of-care objective testing (50% of respondents).

b. Routine screening for VTE using bedside Doppler ultrasonography of the lower extremities or
based on elevated D-dimer levels is not recommended.
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VTE Prophylaxis in non-ICU Hospitalized COVID-19 Patients
Hospitalized acutely-ill medical patients, including those with infections such as viral

pneumonia, are at increased risk for VTE, and antithrombotic practice guidelines recommend
thromboprophylaxis with twice- or thrice-daily subcutaneous unfractionated heparin (UFH) oncedaily subcutaneous low-molecular-weight heparin (LMWH), or fondaparinux to reduce this risk,
although fondaparinux is infrequently used due to its long half-life and reversibility concerns [11,12].
Patients hospitalized with severe COVID-associated pneumonia may have a further heightened risk of
VTE, but this issue remains unresolved. Preliminary reports in patients with severe pneumonia due to
COVID-19 as well as previous reports of severe pneumonias/severe acute respiratory syndromes from
other viruses such as influenza H1N1 or Middle East respiratory syndrome (MERS-CoV) suggest a
multi-fold higher risk for VTE and, in particular, in increased risk for PE [5] . In addition, patientspecific VTE risk factors such as advanced age, a prior history of VTE, a history of or active cancer,
immobility, and thrombophilia, had been incorporated prior to the COVID-19 era to assess overall
VTE risk using standardized VTE risk assessment scores such as Padua VTE or IMPROVE VTE risk
scores [8,13,14] , which had been externally validated [15–17]. A recent study from China in
hospitalized medical patients with COVID-19 reported that 40% of patients had a high risk of VTE
using the Padua VTE model, although the use of thromboprophylaxis was not reported [18] . The
optimal VTE risk stratification scheme for hospitalized COVID-19 patients requires further study,
including the use of very elevated D-dimer levels (>6 times the upper limit of normal [ULN]) that
appear to be a consistent predictor of thrombotic events and poor overall prognosis in this population
[19]. However, given the relatively high rates of VTE found in early reports, the use of a “universal”
thromboprophylactic strategy for all hospitalized patients with COVID-19 appears more appropriate
than an individualized VTE risk assessment approach at present.
All hospitalized patients with COVID-19 should be considered for thromboprophylaxis with

either UFH or LMWH unless there are absolute contraindications. Advantages of LMWH over UFH
include once daily versus twice or thrice daily injections and less heparin-induced thrombocytopenia.
Although some DOACs are approved for in-hospital prophylaxis, these agents should be considered
with caution in COVID-19 patients in whom co-administration of immunosuppressant, antiviral and
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other experimental therapies may potentiate or interfere with DOAC therapy [7]. Many institutions
have adopted prophylaxis protocols that use a “stepped up” or intermediate-dose LMWH dose
regimens based on emerging evidence suggesting increased thrombogenicity with COVID-19,
especially in sicker patients [20] . For patients in whom anticoagulant therapy is contraindicated,
mechanical thromboprophylaxis, preferably with intermittent pneumatic compression devices, should
be utilized, although there is limited evidence of efficacy in hospitalized medically ill patients [11,21].
Guidance Statement 2: VTE prophylaxis in non-ICU hospitalized COVID-19 patients:
a) A universal strategy of routine thromboprophylaxis with standard-dose UFH or LMWH
should be used after careful assessment of bleed risk, with LMWH as the preferred agent.
Intermediate-dose LMWH may also be considered (30% of respondents).

b) VTE prophylaxis recommendations should be modified based on extremes of body weight,
severe thrombocytopenia (i.e. platelet counts of 50,000 x 109 per liter or 25,000 x 109 per liter)
or deteriorating renal function.

VTE Prophylaxis in ICU Hospitalized COVID-19 Patients
Hospitalized COVID-19 patients who are managed in an ICU or CCU setting have an overall

poor prognosis, with the proportion of severe cases approaching 26% (95% CI: 17.4 -34.9) and
reported case-fatality rates of 42% [22]. The presence of co-morbid conditions (e.g., cardiovascular
disease, obesity), a SIC score ≥4, and elevated levels of D-dimer (>6 times ULN), C-reactive protein
and troponins, and other markers of disseminated intravascular coagulopathy (DIC) as assessed by the
ISTH scoring system are associated with a worse prognosis [20,23]. It is uncertain whether changes in
haemostasis parameters are a direct consequence of the SARS-CoV2 virus or a result of a systemic
inflammatory response syndrome (SIRS) that is produced by a cytokine storm after viral infection
[24]. In addition, the heightened prothrombotic tendency in the critically ill hospitalized patients with
COVID-19 pneumonia, leading to VTE and especially, in situ pulmonary artery microthrombi, is
evident in case series and pathologic studies as an endpoint of pulmonary inflammation [25,26]. One
study reported an incidence of VTE of 25% (20/81) and a mortality of 40% (8/20) among patients
hospitalized with severe COVID-19 pneumonia who had VTE; another study found an incidence of
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VTE and arterial thromboembolism of 27% and 3.7%, respectively, in 184 COVID-19 patients who
were in an ICU setting and were receiving standard-dose thromboprophylaxis [3,4]. Lastly, the use of
tissue plasminogen activator in the treatment of COVID-19-associated ARDS was associated with
only transient improvement of pulmonary function [27].
The optimal thromboprophylaxis strategy in the critically ill hospitalized COVID-19 patient

population is uncertain. Emerging clinical data suggests that the use of either prophylactic to
intermediate doses of LMWH (e.g., enoxaparin, 40-60 mg daily) in very sick COVID-19 patients (Ddimer >6 times ULN; SIC score ≥4) is associated with improved outcomes and a better prognosis [20]
. A previous report that assessed treatment-dose UFH in patients with ARDS who were afflicted with
influenza H1N1, found that patients with H1N1-associated ARDS who received therapeutic
anticoagulation had 33-fold fewer VTE events than those treated given prophylactic-dose UFH or
LMWH [5]. Expert clinical guidance statements and clinical pathways from large academic
healthcare systems favor the use of standard-dose regimens with LMWH or UFH (especially for
patients with a creatinine clearance < 30 mL/min), mechanical thromboprophylaxis (intermittent
pneumatic compression) when anticoagulants were contraindicated, use of multimodal (anticoagulant
and mechanical) prophylaxis strategies in the critically ill and completely immobile COVID-19
population [7,28], and the use of VTE risk stratification using either clinical criteria (body mass index
[BMI] >30 kg/m2), VTE risk scores and/or biomarkers (e.g., very elevated D-dimer levels) to suggest
intermediate- or higher-dose LMWH or UFH regimens (e.g. enoxaparin 0.5 mg/kg twice-daily;
enoxaparin 40 mg twice-daily, intravenous UFH targeted to an anti-factor Xa level of 0.30-0.70
IU/mL). Many institutional protocols of hospitalized COVID-19 patients now incorporate obesity
(BMI >30kg/m2) or morbid obesity (BMI > 40kg/m2) to administer intermediate-dose LMWH for

thromboprophylaxis [29].The use of empiric therapeutic-dose anticoagulation has been advocated by
some for the critically ill hospitalized COVID-19 patients, especially in ICU settings; however, data
on the efficacy and safety of this approach is limited [3]. There are ongoing randomized trials that aim
to assess the efficacy and safety of more intense intermediate- to therapeutic-dose versus
prophylactic-dose LMWH in hospitalized COVID-19 patients including COVID Hep
(ClinicalTrials.gov Identifier: NCT04345848), Hep-COVID, and PROTECT COVID 19.
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Guidance Statement 3: VTE prophylaxis in sick ICU Hospitalized COVID-19 patients:
a) Routine thromboprophylaxis with prophylactic-dose UFH or LMWH should be used after
careful assessment of bleed risk. Intermediate-dose LMWH (50% of respondents) can also be
considered in high risk patients. Patients with obesity as defined by actual body weight or BMI
should be considered for a 50% increase in the dose of thromboprophylaxis. Treatment-dose
heparin should not be considered for primary prevention until the results of randomized
controlled trials are available.

b) Multi-modal thromboprophylaxis with mechanical methods (i.e., intermittent pneumonic
compression devices) should be considered (60% of respondents)

Duration of Thromboprophylaxis in Hospitalized COVID-19 Patients
The risk of hospital-associated VTE extends for up to 6 weeks post-hospital discharge in high

VTE risk medically ill patients, including those with pneumonia, sepsis, and any condition requiring
management in an ICU setting [30]. At least 60% of all VTE events in medically ill patients occur in
the post-hospital discharge period, with the first 3 weeks being associated with a greater than 5-fold
increased risk in fatal PE [14]. Earlier studies of extended thromboprophylaxis with DOACs revealed
either limited efficacy or an increase in major bleed risk, and particularly due to these safety concerns,
the most recent antithrombotic guidelines recommended against routine post-discharge
thromboprophylaxis in medically ill patients, including those with pneumonia [12]. However, more
recent data reveals that in selected populations at high VTE risk and low bleed risk, based on key risk
factors or risk models for thrombosis and bleeding, extended-duration thromboprophylaxis for
approximately 4 weeks with prophylactic-dose LMWH (e.g., enoxaparin, dalteparin, tinzaparin) or a
DOAC (e.g. rivaroxaban, betrixaban) provides a net clinic benefit by reducing VTE risk without
incurring a significant increase in the risk of major bleeding [31–33]. This benefit appears more
pronounced in patients whose index hospitalization was due to infectious disease, particularly
pneumonia [34]. Recent data also supports that a modified IMPROVE VTE score using established
cut-offs plus elevated D-dimer (>2 times ULN) identifies patients at an almost three-fold higher risk
for VTE in whom there is a significant benefit for extended-duration thromboprophylaxis [35]. This
finding may be especially relevant for post-discharge VTE risk mitigation in COVID-19 patients. In
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the absence of COVID-19-specific data, it is reasonable to consider extended-duration
thromboprophylaxis with LMWH or a DOAC for at least 2 weeks and up to 6 weeks post-hospital
discharge in selected COVID-19 patients who are at low risk for bleeding and with key VTE risk
factors such as advanced age, stay in the ICU, cancer, a prior history of VTE, thrombophilia, severe
immobility, an elevated D-dimer (>2 times ULN), and an IMPROVE VTE score of 4 or more.
Guidance Statement 4: Duration of VTE prophylaxis for hospitalized COVID-19 patients:
a) Either LMWH (30%) or a DOAC (i.e., rivaroxaban or betrixaban 30% of respondents) can be
used for extended-duration thromboprophylaxis.

b) Extended post-discharge thromboprophylaxis should be considered for all hospitalized
patients with COVID-19 that meet high VTE risk criteria. The duration of post-discharge
thromboprophylaxis can be approximately 14 days at least (50% of respondents), and up to 30
days (20% of respondents).

VTE Treatment in Hospitalized COVID-19 Patients
There are multiple validated and approved strategies to treat hospitalized patients with a new

VTE including the use of UFH/LMWH bridging therapy to dose-adjusted warfarin, the use of
UFH/LMWH lead-in therapy with a switch to dabigatran/edoxaban, or a monotherapy approach with
rivaroxaban/apixaban [36]. In hospitalized COVID-19 patients, parenteral anticoagulation with UFH
or LMWH may have advantages over other strategies due to the absence of known drug-drug
interactions with antiviral agents or investigational therapies used to treat COVID-19. Moreover, the
use of LMWH may have further advantages in this setting due to lack of routine monitoring and
decrease healthcare worker exposure to infection due to frequent blood draws necessary with IV
UFH, which may require higher than usual doses from possible heparin resistance due to acute phase
reactants. DOACs may also have further disadvantages in this setting due to potential drug-drug
interactions via CYP3A4 mechanisms with certain antivirals (i.e., lopinavir/ritonavir) and
immunomodulatory investigational COVID-19 therapies, as well as potential for lack of reversal
agents or specific antidotes in some hospitals [7,28]. However, in the post-hospital discharge setting,
DOACs provide advantages over vitamin K antagonists such as warfarin due to the lack of the need
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for routine monitoring and subsequent minimization of patient contact with the healthcare
environment.
Guidance Statement 5: VTE treatment in hospitalized COVID-19 patients:
a) Established guidelines should be used to treat patients with confirmed VTE, with
advantages of LMWH in the inpatient setting and DOACs in the post-hospital
discharge setting. A change from treatment-dose DOAC or VKA to in-hospital LMWH
should be considered especially for patients in critical care settings or with relevant
concomitant medications, and dependent on renal function and platelet counts.
Anticoagulant regimens should not change based solely on D-dimer levels.
b) A change of anticoagulant regimen (i.e.,from prophylactic or intermediate-dose to
treatment-dose regimen) can be considered in patients without established VTE but
deteriorating pulmonary status or ARDS (50% of respondents).
c) The duration of treatment should be at least 3 months (50% of respondents).

Discussion
COVID-19 is emerging as a highly contagious disease with coagulopathic manifestations that

appear to have unique characteristics. Initial data support a high incidence of thromboembolic disease,
and especially VTE, in hospitalized COVID-19 patients, as well as poorer outcomes for COVID-19
patients with pre-existing cardiovascular disease [3,7]. Due to the risk of infectivity with a need to
minimize contact with healthcare workers and the health system, the diagnosis of VTE in critically ill,
unstable hospitalized COVID-19 patients (especially in the ICU) that may need prone positioning and
may not be able to undergo standard objective testing, the potential for new VTE risk stratification
strategies using novel dosing intensities of established thromboprophylaxis regimens, new paradigms
of post-hospital discharge and extended thromboprophylaxis, and careful considerations of
antithrombotic management due to the potential for drug-drug interactions with investigational or
immunomodulatory therapies, healthcare workers will need to understand special considerations for
the management of VTE in hospitalized COVID-19 patients.
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There is an urgent need for high quality data, especially from randomized controlled trials,

using a coordinated effort by healthcare funding agencies, organizations dedicated to thrombotic
disorders, and professional societies, to answer some of the most urgent questions. These urgent
questions are included in the Table. There is currently one large international registry on VTE
(RIETE) that is capturing data elements for COVID-19 patients with VTE, and other ongoing
registries (CORONA-VTE and CORE-19) that are capturing hospital and post-hospital discharge data
elements for patients with COVID-19. There is also a new registry by the American Heart Association
planned for cardiovascular outcomes of these patients. Lastly, ongoing and planned randomized trials
will address key clinical questions, especially the effect of anticoagulation on outcomes in critically ill
COVID-19 patients and whether more intense thromboprophylaxis strategies improve morbidity and
mortality in hospitalized COVID-19 patients.
This guidance document, using a consensus-based approach, has attempted to provide useful

directions for healthcare practitioners managing VTE-related issues in hospitalized COVID-19
patients. We acknowledge that the lack of an iterative process in our survey produced some guidance
statements that may not have been supported by a majority of expert panel members. As more data is
forthcoming, especially high quality data, there needs to be rapid dissemination of this data that
addresses some of the most urgent clinical issues in this patient population.
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Table. Key Management Issues for VTE in Hospitalized COVID-19 Patients
Topic
Diagnosis of VTE
What is the optimal diagnostic strategy in sick
hospitalized patients?
Should practitioners use elevated D-dimer to guide
diagnosis of VTE?
Prophylaxis of VTE
Should practitioners use VTE risk stratification,
including D-dimer, to determine optimal
thromboprophylaxis strategy?
Should practitioners use higher than usual (i.e.,
intermediate) doses of UFH/LMWH for VTE
prophylaxis? Higher than usual dose (i.e. 50%
increased) in obese patients?
Should practitioners use empiric treatment dose
UFH/LMWH in the management of sick patients
(i.e., D-dimer >6 x ULN, elevated SIC scores)?
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Duration of thromboprophylaxis
What clinical/biomarker criteria and which VTE
RAM should practitioners use for extended
thromboprophylaxis?
What is the optimal agent/duration of extended
thromboprophylaxis?
Treatment of VTE
What is the optimal agent and duration for VTE
treatment? In-hospital? In the outpatient setting?
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VTE

For hospitalized patients with severe COVID-19,

Standard methods using CTPa, V/Q scan, and full

how would you advocate the diagnosis of VTE?

point extremity Dopplers
Pragmatic approach, i.e. bedside POC 2 point LE

Diagnosis in

Compression U/S, bedside TTE to assess presence

Hospitalized

of RV strain
A combination of both depending upon feasibility

30%

20%

50%

COVID-19
patients

20%

Does your institution advocate for routine
screening using LE bedside U/S in severe
hospitalized COVID patients?

20%

Does your institution utilize elevated D-dimers
(i.e, > 2 or 4 X ULN) to initiate VTE screening?

Yes, I Recommended routine pharmacologic

Hospitalized patients

Hospitalized patients in

not in the ICU with

the ICU with severe

COVID-19

COVID-19

90%

90%

60%

50%

20%

30%

0%

0%

0%

10%

30%

50%

10%

20%

prophylaxis
Prophylactic dose LMWH (i.e.
enoxaparin 40mg SQ QD)
Prophylactic dose UFH (i.e. UFH 5000U
SQ BID or TID)

VTE

Prophylactic dose fondaparinux (i.e.
fondaparinux 2.5mg SQ QD)

Prophylaxis

Prophylactic dose DOAC (i.e.

in

rivaroxaban 10mg PO QD; apixaban

Hospitalized

2.5mg PO BID, betrixaban 80mg PO
QD)

COVID-19

What type and dose

patients

of pharmacologic

enoxaparin 40mg SQ BID, 0.5mg/kg SQ

thromboprophylaxis

QD)

do you recommend?

Intermediate dose UFH (i.e. UFH

Intermediate dose LMWH (i.e.

7500U SQ BID or TID)
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Intermediate dose fondaparinux (i.e.

0%

10%

10%

10%

0%

10%

0%

0%

0%

10%

-

60%

fondaparinux 5.0mg SQ QD)
Treatment dose LMWH (i.e.
enoxaparin 1mg/kg SQ BID)
Treatment dose UFH (i.e. UFH IV
adjusted to aPTT)
Treatment dose fondaparinux (i.e.
fondaparinux 7.5 to 10mg SQ QD)
Treatment dose DOAC (i.e.
rivaroxaban 20mg PO QD; apixaban
5.0mg PO BID)

Multimodal prophylaxis with mechanical methods (i.e.
IPCs) in addition to pharmacologic measures for
hospitalized patients in the ICU with severe COVID-19
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For hospitalized patients with severe COVID- 70%
19, do you recommend routine post hospital

Post-hospital

discharge thromboprophylaxis?
Post-hospital

LMWH

30%

discharge

DOAC

30%

UFH

10%

Aspirin

0%

Duration of post-

0-14 days

50%

hospital discharge

14-30 days

20%

> 30 days

0%

Until ambulatory

0%

discharge

thromboprophylaxis thromboprophylaxis
agent

thrombprophylaxis

Do you treat hospitalized COVID-19 patients 90%
with VTE as per your institution's routine

VTE treatment

guidelines?

for hospitalized

For hospitalized COVID-19 patients with 20%

COVID-19

suspected VTE, but without a confirmed

patients

diagnosis of DVT or PE, do you change your
anticoagulant regimen based on elevated Ddimer (i.e. > 2 or 3X ULN?)
For hospitalized COVID-19 patients with 50%
deteriorating pneumonitis or ARDS, but
without a confirmed diagnosis of DVT or PE,
do you change your anticoagulant regimen?
What

is

recommended

your 3 months
3-6 months
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30%
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average duration of 6-12 months

10%

anticoagulation

10%

COVID-19

in Indefinite
patients

with established VTE?

Do you change your VTE
prophylaxis
90%

recommendations based on
extremes of body weight(<
50kg or > 120kg) or BMI?
In obese patients with COVID- >100 kg (40%)
19, at what body weight

>110 kg (10%)

would you increase the dose

>120kg (30%)

of VTE prophylaxis, typically
by 50% (e.g., enoxaparin 40
mg daily to 30 mg twice-
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BMI> 30 (BMI >30 kg/m2 (enoxa 40 mg to
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daily)?

enoxa 40 mg bid) ) (10%)

BMI>40 (I'd prefer to user the BMI (over 40)
(10%)

Special patient

In thrombocytopenic patients

<25 (50%)

populations in

with COVID-19, at what

<30 (10%)

hospitalized COVID-19

platelet count would you not

<50 (30%)

patients

recommend a weightadjusted anticoagulant
prophylaxis regimen such as
enoxaparin 40 mg daily or 30
mg twice-daily (i.e., you
would recommend
mechanical prophylaxis
instead)?
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<100 (10%)

